Harmony Biosciences Holdings, Inc. announced that new safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in patients with Prader-Willi syndrome (PWS) will be highlighted as a poster presentation during a late-breaking abstract session at the 37th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2023," in Indianapolis from June 3-7. Additional presentations by Harmony include an oral presentation covering a pooled analysis of clinically meaningful improvements in adults with narcolepsy, as well as poster presentations detailing the results of a pharmacokinetics study of WAKIX in breast milk and serum in healthy lactating women, and an ongoing prospective observational safety study evaluating WAKIX exposure in pregnant women and their offspring.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.52 USD | +2.14% | +5.72% | -5.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.51% | 173.33Cr | |
+43.64% | 75TCr | |
+40.52% | 63TCr | |
-6.58% | 35TCr | |
+19.72% | 33TCr | |
+8.78% | 30TCr | |
+18.53% | 25TCr | |
+12.42% | 22TCr | |
-0.33% | 22TCr | |
+6.13% | 16TCr |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. to Present New WAKIX Safety and Efficacy Data